
Rohit Patel, former director at Meta Superintelligence Labs, has launched Ndoc, an AI-native workspace designed to replace Microsoft Office and Google Workspace. The platform unifies presentations, data analysis, and code into a single document structure, allowing users to verify underlying Python scripts and datasets directly within the narrative. Patel, who previously focused on reinforcement learning and AI trustworthiness at Meta, built Ndoc using open-source models to reduce inference costs compared to frontier model alternatives. The startup is currently in an enterprise pilot phase with no external funding, aiming to launch a beta version soon while maintaining an open-source file format to avoid vendor lock-in.
Read originalEarlier coverage that leads up to this article, and what followed. Lines connect each piece to the closest one after it, converging here.
© TechCrunch AIxAI's attempt to dismiss the NAACP's Clean Air Act lawsuit failed after a federal judge ruled that its gas turbines are not exempt mobile sources and that plaintiffs have standing. This legal setback confirms that AI infrastructure operators cannot bypass environmental permitting by classifying heavy industrial equipment as temporary or mobile. The ruling forces xAI to face scrutiny over air quality impacts at its Colossus data center, setting a precedent for how large-scale compute facilities are regulated under existing environmental laws.
© TechCrunch AITechCrunch AI · July 9, 2026 · Background
OpenAI · July 16, 2026 · Background
OpenAI · August 12, 2026 · Background
TechCrunch AI · September 29, 2026 · Background
Together AI Blog · October 15, 2026 · Background
OpenAI is scaling back its ambitions as investor appetite for massive AI infrastructure bets cools. The company has lowered its fundraising target from $30 billion to $20 billion, with only $11 billion secured so far against a valuation that has dropped from $1.4 trillion. This retreat signals a growing wariness among Wall Street investors regarding the capital intensity of the AI race, forcing even the most dominant players to adjust their financial expectations.
Exin Therapeutics has demonstrated an AI agent physically controlling a robotic arm to inject drugs into a live mouse's brain. The experiment reveals a critical divergence in model behavior: Anthropic’s Claude Opus refused the procedure due to safety concerns, while Sonnet proceeded. This suggests that as agents gain direct access to physical lab equipment, their alignment and refusal mechanisms become operational realities rather than theoretical safeguards. It marks a shift from AI merely analyzing data to actively manipulating biological systems under human supervision. The team initially tested Claude Opus 5.5, but it halted the injection, citing potential harm. Switching to Claude Sonnet 5 allowed the procedure to complete, though with delays caused by coordinate system glitches. A secondary Opus agent had to fix code errors without knowing a live surgery was underway. Human oversight remains essential as researchers test more complex tasks like craniotomies.